A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102.

Trial Profile

A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors JANSSEN Alzheimer Immunotherapy
  • Most Recent Events

    • 06 Aug 2012 Status changed from active, no longer recruiting to discontinued.
    • 19 Sep 2011 Planned End Date changed from 1 Jun 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 24 Sep 2009 Planned end date changed from 1 Dec 2008 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top